Centro de Referencia para Lactobacilos-Consejo Nacional de Investigaciones Científicas y Técnicas, San Miguel de Tucumán, Argentina.
Lett Appl Microbiol. 2012 Jan;54(1):18-25. doi: 10.1111/j.1472-765X.2011.03166.x. Epub 2011 Nov 23.
To evaluate the effect of oral administration of Lactobacillus fermentum CRL1446 on the intestinal feruloyl esterase (FE) activity and oxidative status of mice.
Adult Swiss albino mice received Lact. fermentum CRL1446 at the doses 10(7) and 10(9) cells per day per mouse for 2, 5, 7 and 10 days. Intestinal FE activity, intestinal microbiota counts, plasmatic thiobarbituric acid-reactive substances (TBARS) percentage and glutathione reductase (GR) activity were determined. Mice that received Lact. fermentum CRL1446 at the dose 10(7) cells per day for 7 days showed a twofold increase in total intestinal FE activity, compared to the nontreated group. In large intestine content, FE activity increased up to 6·4 times. No major quantitative changes in colonic microbiota were observed in treated animals. Administration of this strain produced an approx. 30-40% decrease in the basal levels of plasmatic TBARS and an approx. twofold increase in GR activity from day 5 of feeding with both doses.
Oral administration of Lact. fermentum CRL1446 to mice increases total intestinal FE activity, decreases the basal percentage of plasmatic lipoperoxides and increases GR activity.
Lactobacillus fermentum CRL1446 could be orally administered as a dietary supplement or functional food for increasing the intestinal FE activity to enhance the bioavailability of ferulic acid, thus improving oxidative status.
评估口服发酵乳杆菌 CRL1446 对小鼠肠道阿魏酸酯酶(FE)活性和氧化状态的影响。
成年瑞士白化病小鼠每天接受 10(7)和 10(9)个细胞/只的发酵乳杆菌 CRL1446,连续 2、5、7 和 10 天。测定肠道 FE 活性、肠道微生物群计数、血浆硫代巴比妥酸反应物质(TBARS)百分比和谷胱甘肽还原酶(GR)活性。与未处理组相比,每天接受 10(7)个细胞/只发酵乳杆菌 CRL1446 7 天的小鼠总肠道 FE 活性增加了两倍。大肠内容物中 FE 活性增加了 6.4 倍。处理动物的结肠微生物群没有观察到主要的定量变化。该菌株的给药使基础血浆 TBARS 水平降低约 30-40%,两种剂量从喂养第 5 天起 GR 活性增加约 2 倍。
口服发酵乳杆菌 CRL1446 可增加小鼠总肠道 FE 活性,降低基础血浆脂质过氧化物百分比,并增加 GR 活性。
发酵乳杆菌 CRL1446 可作为膳食补充剂或功能性食品口服给药,以增加肠道 FE 活性,从而提高阿魏酸的生物利用度,进而改善氧化状态。